189 related articles for article (PubMed ID: 23370512)
61. Exploration of the impact of stereochemistry on the identification of the novel translocator protein PET imaging agent [(18)F]GE-180.
Chau WF; Black AM; Clarke A; Durrant C; Gausemel I; Khan I; Mantzilas D; Oulie I; Rogstad A; Trigg W; Jones PA
Nucl Med Biol; 2015 Sep; 42(9):711-9. PubMed ID: 26072270
[TBL] [Abstract][Full Text] [Related]
62. [Development of ADCs Using Molecular Imaging].
Yasunaga M; Manabe S; Tsuji A; Furuta M; Ogata K; Koga Y; Fujiwara Y; Saga T; Matsumura Y
Yakugaku Zasshi; 2017; 137(5):535-544. PubMed ID: 28458285
[TBL] [Abstract][Full Text] [Related]
63. Clinical research: the future of the molecular imaging technologist-a white paper presented by members of the graduate stakeholders committee of the SNMMI technologist section.
Holbrook S; Baldwin J; Gilmore CD; Henkin R; Hubble W; Kiss C; Bires AM; Mann A; Nelson KP; Owen MA; Sobey K; Stuckey A; Wenzel-Lamb N; Wilkinson D; Wintering NA
J Nucl Med Technol; 2014 Sep; 42(3):228-32. PubMed ID: 25125447
[No Abstract] [Full Text] [Related]
64. Radiolabeled inorganic nanoparticles for positron emission tomography imaging of cancer: an overview.
Chakravarty R; Goel S; Dash A; Cai W
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):181-204. PubMed ID: 28124549
[TBL] [Abstract][Full Text] [Related]
65. Radiolabeling Silica-Based Nanoparticles via Coordination Chemistry: Basic Principles, Strategies, and Applications.
Ni D; Jiang D; Ehlerding EB; Huang P; Cai W
Acc Chem Res; 2018 Mar; 51(3):778-788. PubMed ID: 29489335
[TBL] [Abstract][Full Text] [Related]
66. Multimodal Molecular Imaging Reveals High Target Uptake and Specificity of 111In- and 68Ga-Labeled Fibrin-Binding Probes for Thrombus Detection in Rats.
Oliveira BL; Blasi F; Rietz TA; Rotile NJ; Day H; Caravan P
J Nucl Med; 2015 Oct; 56(10):1587-92. PubMed ID: 26251420
[TBL] [Abstract][Full Text] [Related]
67. PET Imaging in Psychoneuroimmunology Research.
Hannestad J
Methods Mol Biol; 2018; 1781():287-307. PubMed ID: 29705853
[TBL] [Abstract][Full Text] [Related]
68. [Significance of imaging biomarkers in exploratory clinical trials].
Takano H; Suhara T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):55-9. PubMed ID: 19562942
[TBL] [Abstract][Full Text] [Related]
69. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products.
Nagai S; Ozawa K
Curr Gene Ther; 2017; 17(1):17-28. PubMed ID: 28382858
[TBL] [Abstract][Full Text] [Related]
70. Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.
Pantel AR; Mankoff DA
Cancer Lett; 2017 Feb; 387():25-31. PubMed ID: 27195912
[TBL] [Abstract][Full Text] [Related]
71. SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic.
Wang X; Feng H; Zhao S; Xu J; Wu X; Cui J; Zhang Y; Qin Y; Liu Z; Gao T; Gao Y; Zeng W
Oncotarget; 2017 Mar; 8(12):20476-20495. PubMed ID: 28108738
[TBL] [Abstract][Full Text] [Related]
72. Accelerating safe drug development: an ideal approach to approval.
Grever MR
Hematology Am Soc Hematol Educ Program; 2013; 2013():24-9. PubMed ID: 24319158
[TBL] [Abstract][Full Text] [Related]
73. Challenges in molecular imaging of Parkinson's disease: a brief overview.
Kassiou M; Banati R; Holsinger RM; Meikle S
Brain Res Bull; 2009 Feb; 78(2-3):105-8. PubMed ID: 18790022
[TBL] [Abstract][Full Text] [Related]
74. Application of cardiac molecular imaging using positron emission tomography in evaluation of drug and therapeutics for cardiovascular disorders.
Yoshinaga K; Chow BJ; dekemp RA; Thorn S; Ruddy TD; Davies RA; DaSilva JN; Beanlands R
Curr Pharm Des; 2005; 11(7):903-32. PubMed ID: 15777243
[TBL] [Abstract][Full Text] [Related]
75. Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.
Arai H; Ouchi Y; Toba K; Endo T; Shimokado K; Tsubota K; Matsuo S; Mori H; Yumura W; Yokode M; Rakugi H; Ohshima S
Geriatr Gerontol Int; 2015 Jun; 15(6):673-87. PubMed ID: 25656311
[TBL] [Abstract][Full Text] [Related]
76. Imaging in Central Nervous System Drug Discovery.
Gunn RN; Rabiner EA
Semin Nucl Med; 2017 Jan; 47(1):89-98. PubMed ID: 27987561
[TBL] [Abstract][Full Text] [Related]
77. Relationship Between the Review Time and Various PMDA Consultations in Recent New Drug Approval Cases in Japan.
Nishiyama K; Toyoshima S; Yamada H; Suzuki H; Nagai N
Ther Innov Regul Sci; 2018 Nov; 52(6):731-738. PubMed ID: 29714577
[TBL] [Abstract][Full Text] [Related]
78. The usefulness of radiotracers to make the body biochemically transparent.
Johannsen B
Amino Acids; 2005 Dec; 29(4):307-11. PubMed ID: 15924214
[TBL] [Abstract][Full Text] [Related]
79. Applications of molecular imaging in drug discovery and development process.
Ahn BC
Curr Pharm Biotechnol; 2011 Apr; 12(4):459-68. PubMed ID: 21342108
[TBL] [Abstract][Full Text] [Related]
80. Non-invasive imaging in experimental medicine for drug development.
Matthews PM; Rabiner I; Gunn R
Curr Opin Pharmacol; 2011 Oct; 11(5):501-7. PubMed ID: 21570913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
